Company Directory - Research & Development
We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer. Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients.
We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.
Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies.
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system.
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells. We are searching for novel therapies that suppress or over-ride these harmful pathways and keep cells healthy. It’s a concept known as synthetic viability.
The purpose of Agilent Research Laboratories is to power Agilent’s growth through breakthrough science and technology.
Akari Therapeutics was established in 2005 in the UK. We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.
Alacris Theranostics GmbH is a Berlin-based company founded in 2008 by pioneers in the fields of technology development, genomics, new generation sequencing applications and systems biology. The company’s core technologies have been in continuous development since 2000.
At Alchemab, we are harnessing the power of our immune system to cure disease. We turn drug discovery on its head by using nature’s most effective search engine: adaptive immunity. We identify “elite controllers” – or especially resilient individuals – and learn how they overcome or resist disease.
Alcresta develops novel products that deliver enzymatic solutions to those living with rare diseases. Based in Massachusetts, we have achieved significant commercial milestones, created an extensive intellectual property portfolio, optimized production capabilities, and developed exciting scientific data supporting its products and technology platform.
Alcyomics is a Newcastle based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for predicting adverse immune reactions as well as determining efficacy of novel compounds including pharmaceuticals, chemicals and cosmetics.
We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases.
We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms.
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better.
Amarna Therapeutics is a privately held Biotech company founded in 2008. Its head office is located in Leiden (The Netherlands), and its research facility in Seville (Spain).
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.
AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.
